By Andrew Mitchell, Intralinks
Over the past several years, we’ve seen drug developers drop the blockbuster-era dream of fully-integrated pharmaceutical companies in place of an externalized, networked model of R&D.
Almost all of the leading drugmakers have moved to this model to save money on production, make workflow more efficient, speed up processes, and stay competitive. This shift to the externalized model really began with the impending loss of exclusive patent rights on blockbuster drugs and the lack of new drugs to replace lost sales from the patent rights with the hit of the financial crisis. Pharmaceutical companies realized they couldn’t do their entire R&D in house effectively.